| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
Vor Biopharma Inc.$19.14
-0.61 (-3.09%)
D 31Pipeline Score Richly Valued Biotech · Clinical
Market Cap
776.48 M
EPS
-333.48
P/E Ratio
-
Value Trade
8.78 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
17.59 M
Operating CF
-38.25 M
Total Assets
506.75 M
Total Liabilities
657.17 M
Equity
-150.42 M
D/E Ratio
12,345
-3.76 %
Week
-6.34 %
1 Month
7.99 %
3 Month
111.67 %
6 Month
-96.75 %
5 Year
-98.29 %
All Time
Cash Data
Cash Position
491.52 M
Monthly Burn
12.75 M
Runway
36.9 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
2.18 M
52 Week Range
3.30 - 65.80
% held by Insiders
46.73 %
% held by Institutions
41.09 %
Enterprise Value
287.90 M
Total Shares
41.52 M
Short %
20.61 %
Float Shares
29.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vor Biopharma Inc.
305Total events
5Upcoming
62Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
2027-H1
T1Topline Readout
Topline data anticipated from global Phase 3 trial UPSTREAM MG for telitacicept in gMG
Event history 300
Jun 8, 2026
▲NMPA NDA ApprovalTelitaciceptApprovedEx-US Regulatory
NMPA conditional approval for IgA nephropathy
IgA nephropathysource ↗
Jun 8, 2026
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Phase 3 TELIGAN met primary endpoint
IgA nephropathysource ↗
Jun 8, 2026
▲PublicationTelitaciceptApprovedPresentation
TELIGAN results published in New England Journal of Medicine
IgA nephropathysource ↗
Jun 3, 2026
May 14, 2026
▲Full ResultsTelitaciceptApprovedClinical Data
Interim analysis of TELIGAN published in NEJM
IgA nephropathysource ↗
May 14, 2026
▲Primary Endpoint MetTelitaciceptApprovedClinical Data
Primary endpoint met: statistically significant reduction in proteinuria at week 39
IgA nephropathysource ↗
May 13, 2026
◆Enrollment UpdateTelitaciceptApprovedTrial
Enrollment ongoing for Phase 3 UPSTREAM SjD trial of telitacicept in SjD
primary Sjögren's diseasesource ↗
Mar 30, 2026
▲First Patient DosedTelitaciceptApprovedTrial
First patient dosed in global Phase 3 trial UPSTREAM SjD for telitacicept in primary Sjögren's disease
primary Sjögren's diseasesource ↗
Mar 30, 2026
●Enrollment UpdateTelitaciceptApprovedTrial
Enrollment ongoing globally in Phase 3 trial UPSTREAM MG for telitacicept in gMG
generalized myasthenia gravissource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $114M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 37%
Micro Cap (rank 575 of 911)
Percentile RankVor Biopharma Inc. faces pipeline headwinds (31/100), with $286M risk-adjusted pipeline value, led by Telitacicept in Primary Sjogren's Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telitacicept Monoclonal antibody | Primary Sjogren's Disease | Phase 3 | NCT07404865 | 57% | $286M | RECRUITING | 250 | FAST | B (67) | Jan 1, 2029 | HIGH_RISK | LOW Jun 4, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
telitacicept | IgA nephropathy | Phase 3 | 2026-06-08 | UPCR reduction: 59%; placebo adjusted reduction: 55% | Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TEL Read More | |
telitacicept | IgA nephropathy | Phase 3 | 2026-06-08 | UPCR reduction: 59%; placebo adjusted reduction: 55% | Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TEL Read More | |
telitacicept | IgA nephropathy | Phase 3 | 2026-06-08 | UPCR reduction: 59%; placebo adjusted reduction: 55% | Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TEL Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VOR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VOR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-01-15 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VOR▼ -3.1%today
Vor Bio Appoints David Zaccardelli to Board of Directors
Vor Bio has appointed David Zaccardelli to its Board of Directors, bringing over 20 years of biopharmaceutical leadership experience. His previous successes include leading Verona Pharma through significant growth and FDA approval. Zaccardelli's expertise is expected to aid Vor Bio in advancing telitacicept through global Phase 3 development for autoimmune diseases.
Read more →VORTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TEL
Vor Bio's telitacicept has received conditional approval from China's NMPA for the treatment of IgA nephropathy (IgAN), marking it as the first approved BAFF/APRIL-targeting therapy for this condition. The approval is based on positive efficacy results from the Phase 3 TELIGAN trial, which showed significant reductions in urinary protein-to-creatinine ratio. Vor Bio maintains exclusive rights for global commercialization, while RemeGen is responsible for its development within China. This approval underscores the potential of telitacicept in addressing the underlying immunological aspects of IgAN and other autoimmune diseases.
Read more →VOR▼ -6.2%on this news
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Vor Bio has granted stock options and restricted stock units to 10 new employees as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price equal to the closing price on the grant date. The vesting schedule for both stock options and RSUs spans four years, contingent on continued employment.
Read more →VORVor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Bio will participate in the 2026 Jefferies Global Healthcare Conference, providing a corporate update during a fireside chat. The presentation is scheduled for June 3, 2026, and will be accessible via a live webcast. Vor Bio is focused on advancing its telitacicept treatment for autoimmune diseases through Phase 3 clinical development.
Read more →VOR▼ -5.3%on this news
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Vor Bio has announced positive interim analysis results from the Phase 3 TELIGAN trial of telitacicept, published in The New England Journal of Medicine. The study reported a significant 55% relative reduction in proteinuria and stable kidney function after 39 weeks of treatment compared to placebo. The results suggest the potential of telitacicept as a leading therapy for IgA nephropathy and other autoimmune diseases. The therapy is currently undergoing regulatory evaluations and might be positioned as a best-in-class dual BAFF/APRIL treatment.
Read more →VORVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio reported its financial results for Q1 2026, highlighting ongoing enrollment in Phase 3 trials for telitacicept in generalized myasthenia gravis and primary Sjögren’s disease. The company maintains a strong cash position of $491.5 million, expected to support operations until early 2029. Despite an increased net loss, the company is optimistic about the potential of telitacicept as a foundational therapy in autoimmune diseases.
Read more →VOR▲ +6.2%on this news
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio has announced the granting of stock options and restricted stock units to six new employees as inducements under Nasdaq Listing Rule 5635(c)(4). The granted instruments include options to purchase 53,400 shares and 11,350 RSUs, set to vest over a four-year period. This strategic move aims to enhance the company's capacity to advance its biotechnology efforts, particularly in the treatment of autoimmune diseases with its lead candidate, telitacicept.
Read more →VORVor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Bio has reported its financial results for Q4 and full year 2025, highlighting the initiation of a global Phase 3 trial for telitacicept in primary Sjögren's disease. The company secured a $75 million private placement to support its clinical development efforts. Despite a significant net loss for the year, Vor Bio maintains a strong cash position, expected to fund operations into early 2029.
Read more →VORVor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
Vor Bio has initiated the Phase 3 UPSTREAM SjD trial by dosing the first patient with telitacicept for primary Sjögren’s disease. This trial aims to evaluate the efficacy and safety of telitacicept, a unique BAFF/APRIL inhibitor, in a patient population that currently lacks approved disease-modifying therapies. The trial will involve approximately 250 patients and assess key disease activity metrics.
Read more →VOR▲ +6.7%on this news· ran to +28% by day 3shared move
Vor Bio Announces $75 Million Private Placement with TCGX
Vor Bio has announced a $75 million private placement to fund the clinical development of telitacicept, a treatment for autoimmune diseases. The financing, led by TCGX, will support ongoing Phase 3 trials for generalized myasthenia gravis and primary Sjögren's disease. The private placement is expected to close around March 30, 2026.
Read more →VORVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 23, 2026
Vor Bio has granted stock options and restricted stock units to eight new employees as part of its Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options, which have a ten-year term, will vest over four years, encouraging employee retention. This move reflects Vor Bio's commitment to growth as it advances its treatment for autoimmune diseases.
Read more →VOR▲ +13.8%on this news
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
Vor Bio will participate in the 46th Annual TD Cowen Health Care Conference in Boston, scheduled for March 2, 2026. The company will present its advancements in the treatment of autoimmune diseases and host one-on-one investor meetings. A live webcast of the presentation will be available for 90 days on their website.
Read more →VORGlobal Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026 Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meanin
Vor Biopharma Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, discussing its forward-looking statements and the development of telitacicept for autoimmune diseases. The company outlined its expected milestones, including upcoming Phase 3 trials for Myasthenia Gravis and Sjögren's disease. Notably, Vor maintains a cash runway into mid-2028, which should support key development activities. However, the company acknowledged potential risks associated with clinical trials and regulatory approvals.
Read more →VOR▲ +10.3%on this news· ran to +28% by day 1
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vor Bio, a clinical-stage biotechnology company, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company will present and host one-on-one investor meetings on January 13, 2026. Vor Bio is focused on advancing its novel dual-target fusion protein, telitacicept, through Phase 3 development aimed at treating autoimmune diseases. The presentation will be available via a live webcast, enhancing investor engagement.
Read more →VOR▲ +7.4%on this news
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma Inc. has appointed Andrew Levin, M.D., Ph.D., and Wouter Joustra to its Board of Directors. Their expertise in life sciences investment and strategic oversight is expected to support the company's Phase 3 programs and enhance shareholder value. This follows a significant $150M PIPE financing that included participation from both new board members.
Read more →VOR▲ +8%on this news· ran to +26% by day 1
Vor Bio Announces $150 Million Private Placement
Vor Bio has announced a private placement to sell 13,876,032 shares at $10.81 each, aiming to raise approximately $150 million. The funds will support the clinical development of telitacicept, particularly for ongoing Phase 3 trials in myasthenia gravis and primary Sjögren's disease. The placement involves participation from several institutional investors and is expected to close around December 18, 2025.
Read more →VORVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
Vor Biopharma's announcement regarding a late-breaking poster presentation at ACR Convergence 2025 lacks specific details about the Phase 3 clinical study on Primary Sjögren's Disease. The article primarily focuses on employment policies and procedures rather than the study itself. As a result, it does not convey any relevant information about the clinical findings or implications of the presentation.
Read more →VORtest in the news 3
Vor Biopharma has outlined its employment procedures, emphasizing that all opportunities are managed by its in-house Human Resources Department. Agency staff and independent recruiters are instructed to contact HR directly for candidate presentations. The company does not accept unsolicited resumes unless there is a signed agency agreement in place.
Read more →VORtest in the news 2
Vor Biopharma has outlined its employment policies, emphasizing that all job opportunities are managed by its in-house Human Resources Department. The company requests that agency staff and independent recruiters contact HR directly for candidate presentations. Additionally, unsolicited resumes will not be accepted unless accompanied by a signed agency agreement.
Read more →VORVor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Vor Bio reported strong third quarter results, highlighting the efficacy of telitacicept in treating autoimmune diseases. The company raised $115 million in a public offering and expanded its leadership team to enhance development capabilities. Positive Phase 3 results in Sjögren's disease and ongoing trials in generalized myasthenia gravis underscore telitacicept's potential as a leading treatment option.
Read more →VOR▼ -47.7%on this newsshared move
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
Vor Biopharma Inc. has announced the pricing of a public offering of 10 million shares at $10.00 each, aiming to raise $100 million. The offering is set to close on November 12, 2025, pending customary conditions. The company has also granted underwriters a 30-day option for an additional 1.5 million shares. This move supports Vor Bio's ongoing development of its treatment for autoimmune diseases.
Read more →VORVor Bio Announces Proposed Public Offering of $100 Million of Common Stock
Vor Biopharma Inc. has announced a proposed public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. This offering is part of Vor Bio's strategy to fund the clinical development of its candidate drug, telitacicept, for treating autoimmune diseases. The company states that the offering is subject to market conditions and other factors, meaning completion is not guaranteed. The public offering follows a shelf registration previously filed with the SEC.
Read more →VORTelitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Vor Bio announced that telitacicept successfully met its primary endpoint in a Phase 3 study for IgA nephropathy, showing a significant reduction in proteinuria. The study also reported statistically significant improvements in all key secondary endpoints, indicating potential disease-modifying effects. The treatment was well-tolerated, with a favorable safety profile. A Biologics License Application has been submitted in China for this indication.
Read more →VORVor Bio to Participate in Upcoming Investor Conferences
Vor Bio, a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences. The events include a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on November 12, 2025, and another at the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Miami, FL. The company is focused on advancing its treatment for autoimmune diseases through its lead candidate, telitacicept.
Read more →VOR▼ -7.1%on this news· ran to -21% by day 3
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Vor Bio has appointed Dr. Jeremy Sokolove as Chief Medical Officer, bringing over 20 years of experience in rheumatology and autoimmune disease research. His expertise is expected to strengthen Vor Bio's clinical strategy, particularly in advancing their dual BAFF/APRIL approach. Dr. Sokolove expressed enthusiasm for the potential of telitacicept to improve patient outcomes.
Read more →VOR▼ -7.1%on this news· ran to -21% by day 3shared move
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio has granted stock options and restricted stock units to 20 new employees as part of their inducement plan. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), includes 113,478 stock options and 24,319 RSUs. The options have a ten-year term with a vesting schedule over four years, aimed at incentivizing employee retention.
Read more →VORTelitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Vor Bio's telitacicept shows promising results in a 48-week Phase 3 open-label extension study for generalized myasthenia gravis (gMG). All patients on telitacicept achieved significant improvements in daily living activities, with a mean reduction of 7.5 points in MG-ADL. The data suggests a favorable safety profile and potential for global best-in-disease status, with ongoing trials in multiple countries.
Read more →VORGlobal Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sj gren's Disease
Vor Biopharma Inc. presented data from a 48-week Phase 3 clinical trial for telitacicept in treating primary Sjogren's disease. The results indicated that telitacicept achieved statistically significant improvements in patient-reported outcomes, with a high percentage of participants experiencing symptom relief. This therapy's dual mechanism targeting BAFF and APRIL provides a promising approach to managing the disease, positioning telitacicept as a potential first in class for disease modification in this and other conditions. The findings underscore a substantial unmet medical need in this patient population.
Read more →VORVor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Vor Bio will host a live webcast on October 28, 2025, to discuss late-breaking Phase 3 clinical data for telitacicept in primary Sjögren’s disease. The presentation will include key efficacy and safety results from the trial conducted in collaboration with RemeGen Co., Ltd. The webcast will be accessible for replay on the company's investor website.
Read more →VORVor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
Vor Bio announced that clinical data from a Phase 3 study of telitacicept for IgA nephropathy will be presented at the ASN Kidney Week 2025. The study, sponsored by RemeGen, showed a 55% reduction in proteinuria at 39 weeks compared to placebo. The presentation is scheduled for November 8, 2025, and could lead to further approvals in China.
Read more →VORVor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Vor Bio announced the publication of a Phase 3 study in China demonstrating that telitacicept significantly improves disease activity in systemic lupus erythematosus. The study showed a 67.1% response rate in patients treated with telitacicept compared to 32.7% with placebo. The results suggest telitacicept could become a new standard of care for lupus treatment.
Read more →VOR▲ +12%on this news· ran to +24% by day 1
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Vor Bio has appointed Dr. Navid Z. Khan as its new Chief Medical Affairs Officer. Dr. Khan brings over two decades of experience in medical affairs and has successfully overseen numerous product launches in neurology and immunology. His expertise is expected to strengthen Vor Bio's efforts in advancing its autoimmune disease therapies, particularly the novel dual-target fusion protein, telitacicept. The appointment takes place as Vor Bio aims for significant advancements in transforming autoimmune disease treatments.
Read more →VORVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
Vor Bio has announced that 48-week clinical data from its Phase 3 study of telitacicept in adults with generalized myasthenia gravis will be presented as an oral presentation at the AANEM Annual Meeting in San Francisco. The study, which demonstrated a notable improvement in patients' daily living activities, underscores Vor Bio's advancement in autoimmune therapeutics. Telitacicept is currently under Phase 3 clinical development and is already approved for several other autoimmune conditions in China. The upcoming presentation will occur on October 29, 2025.
Read more →VORVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Vor Bio announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum, which includes a fireside chat and virtual investor meetings. The event is scheduled for September 15, 2025, and will highlight Vor Bio's advancements in autoimmune disease treatment. The company is currently progressing its drug, telitacicept, through Phase 3 clinical development. The presentation will be available for live streaming and on-demand access through the company's website.
Read more →VORForward Looking Statement This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" o
Vor Biopharma Inc. provided an update on its forward-looking statements regarding the development of telitacicept, a BAFF/APRIL inhibitor for autoimmune diseases. The company highlights the potential of telitacicept in treating generalized myasthenia gravis and primary Sjögren's disease, anticipating it to be a best-in-class treatment. Vor Biopharma currently holds a strong cash position that extends its runway for critical milestones into early 2027. However, the company acknowledged various risks including uncertainties in clinical trials and regulatory approvals.
Read more →VORVor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio has appointed Adi Osovsky, S.J.D. as General Counsel, a move aimed at strengthening its leadership during a critical growth phase. With 17 years of experience in corporate counsel within the biotech sector, Dr. Osovsky is expected to provide invaluable guidance on governance and compliance issues. Her previous roles include serving as Executive VP and Head of Legal at iTeos Therapeutics, where she led corporate legal activities. Vor Bio's initiatives include advancing its dual-target fusion protein, telitacicept, through Phase 3 clinical development for autoimmune diseases.
Read more →VORVor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Vor Bio has appointed Dallan Murray as Chief Commercial Officer, effective immediately, to enhance its commercial strategy as it aims for the potential commercialization of telitacicept. Murray brings over 25 years of experience in leading commercial organizations within biotechnology. He is expected to play a crucial role as Vor Bio advances telitacicept through global Phase 3 trials, with hopes of addressing serious autoimmune diseases. The appointment reflects the company's commitment to expanding its growth strategy during a pivotal moment in its development.
Read more →VOR▼ -7.2%on this news
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Vor Bio has appointed Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors. Cumbo, a seasoned executive with extensive experience in commercial leadership, and Detheux, known for his role in raising substantial capital for biopharmaceuticals, will bring valuable insights to Vor Bio's strategy. Their appointments come at a pivotal time as the company seeks to advance its key asset, telitacicept, through late-stage development in the treatment of autoimmune diseases. Both leaders expressed enthusiasm for the opportunity to contribute to Vor Bio's mission and growth.
Read more →VOR▲ +12.3%on this newsshared move
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in global clinical development of autoimmune diseases. Her previous role at RemeGen involved leading clinical trials and achieving important regulatory approvals for the drug telitacicept. Dr. Zuraw's extensive career includes senior leadership positions at reputable companies, which equips her to advance Vor Bio's late-stage programs. The company aims to leverage her expertise to drive forward the clinical development of telitacicept, aimed at addressing serious conditions globally.
Read more →VOR▼ -9.1%on this news
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership
Vor Bio has appointed Sandy Mahatme as its new Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mahatme, who brings over 30 years of leadership experience in the biotechnology sector, previously co-founded National Resilience and raised significant capital for various companies such as Sarepta Therapeutics. He is expected to play a pivotal role in advancing Vor Bio's telitacicept through its Phase 3 clinical development for autoimmune diseases. His appointment comes at a critical time as the company aims to strengthen its market position and drive growth.
Read more →VOR▼ -11.7%on this news· ran to +65% by day 3
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio has granted CEO Jean-Paul Kress a stock option to purchase over 83 million shares as part of his employment inducement under Nasdaq Listing Rule 5635(c)(4). The stock option, with a term of ten years and an exercise price matching the closing stock price at the time of the grant, will vest over four years. Vor Bio continues to progress in the development of its innovative treatment for autoimmune diseases, particularly focusing on its lead candidate, telitacicept.
Read more →VOR▲ +74.3%on this news· ran to +409% by day 3
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant f
Vor Bio has entered into an exclusive global license agreement with RemeGen for the development and commercialization of telitacicept, a dual-target recombinant fusion protein currently in Phase 3 clinical trials for autoimmune conditions. Vor Bio will pay RemeGen a total of $125 million initially, with potential milestones exceeding $4 billion. Additionally, Jean-Paul Kress has been appointed as the new CEO, replacing Robert Ang. The partnership aims to expand the reach of telitacicept, which is already approved in China for various autoimmune diseases.
Read more →VOR▲ +74.3%on this news· ran to +409% by day 3
Vor Bio Announces $175 Million Private Placement
Vor Bio has announced a private placement expected to generate approximately $175 million, which will be used to further develop its clinical pipeline and for general corporate purposes. The securities purchase agreement includes prefunded warrants to acquire shares at $0.25 each. The financing has garnered interest from notable investors and is anticipated to close on June 27, 2025, pending customary closing conditions. Vor Bio is focused on advancing its product telitacicept for autoimmune diseases, although the securities involved remain unregistered at this time.
Read more →VOR▼ -70.1%on this news
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Vor Bio has announced the initiation of a process to explore various strategic alternatives to maximize shareholder value due to challenging fundraising conditions. The company will wind down its clinical and manufacturing operations, leading to a workforce reduction of approximately 95%, while retaining a small number of employees for ongoing compliance and strategic exploration. Currently, Vor Bio has significant cash reserves of $91.9 million, but there is no defined timeline for these strategic alternatives, making future outcomes uncertain.
Read more →VORVor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Vor Bio reported financial results for Q4 and full year 2024, highlighting advancements in their clinical trials for trem-cel and VCAR33. The company plans to release new data in 2025 and has made significant progress in its clinical trials, maintaining strong enrollment. They successfully completed a $55.6 million private placement to enhance their financial position. However, Vor Bio continues to face substantial net losses, emphasizing the challenges inherent in clinical development and operational funding.
Read more →VORVor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Vor Bio presented research at the TANDEM Meetings examining barriers to patient enrollment in cell and gene therapy (CGT) trials. The study identified challenges such as logistical complexities and the need for enhanced patient education. Despite these obstacles, survey participants reiterated their commitment to offering CGT options, underscoring their potential for patient care. The insights gained aim to streamline processes and improve the overall experience for patients considering these innovative treatments.
Read more →VOR▼ -5.6%on this news
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Vor Bio (Nasdaq: VOR) has announced its participation in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The event will feature a fireside chat and virtual 1x1 investor meetings scheduled for February 12. Vor Bio specializes in cell and genome engineering, aiming to transform therapies for patients with blood cancers by developing targeted treatments using engineered stem cells. A live webcast of the fireside chat will be accessible on their website.
Read more →VORVor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
Vor Bio has appointed Mr. Erez Kalir to its Board of Directors as part of a strategic move following a recent private investment in public equity financing. Kalir, who has a strong background in life sciences and technology investment, is expected to contribute significantly to the company’s growth, particularly in its efforts to revolutionize treatments for blood cancer. With his extensive experience and insights from the biotech sector, Vor Bio aims to advance its clinical programs and regulatory approval process. The company is focused on utilizing engineered hematopoietic stem cells for targeted therapies.
Read more →VOR▲ +51.6%on this news
Vor Bio Announces $55.6 Million Private Placement
Vor Bio has announced a private placement financing expected to yield approximately $55.6 million, which will extend its cash runway. This financing, led by investor Reid Hoffman, includes the issuance of shares and warrants, and aims to support the development of its clinical trials. The company plans to release updated clinical data from its VBP301 and VBP101 trials in 2025, with the PIPE projected to close on December 30, 2024. Vor Bio's innovative therapies target blood cancers and utilize CRISPR technology to potentially improve patient outcomes.
Read more →VOR▲ +51.6%on this news
Vor Bio Announces $55.6 Million Private Placement Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of tr
Vor Bio has announced a successful private placement, raising approximately $55.6 million aimed at extending their financial runway for ongoing clinical trials. They are set to provide updated clinical data from their Phase 1/2 trials, VBP301 for VCAR33 ALLO and VBP101 for trem-cel, in 2025. This funding will not only support the clinical development of their pipeline but also enhance their corporate capacity. The announcement has attracted new investment, highlighting interest in Vor Bio's innovative approach to blood cancer therapies.
Read more →VOR▲ +26.9%on this news
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design Preliminary data sugge
Vor Bio announced promising clinical updates from its VBP101 study, showing durable engraftment and improved patient outcomes for those with relapsed/refractory AML receiving trem-cel and Mylotarg. The FDA provided supportive feedback on the proposed registrational trial design, further validating the company's approach. Early data indicates a broader therapeutic window and improved relapse-free survival compared to existing options. Vor Bio remains optimistic about the potential of their product candidates in changing standard treatments for blood cancers.
Read more →VORVor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Bio, a clinical-stage cell and genome engineering company, will participate in the Stifel 2024 Healthcare Conference. The event includes a fireside chat scheduled for November 18, 2024, in New York City. Vor Bio's work focuses on engineering hematopoietic stem cells to improve post-transplant therapies for patients with blood cancers. Investors can access a live webcast of the discussion via Vor Bio's website.
Read more →VORVor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Vor Bio reported its third quarter financial results, showcasing operational achievements and promising clinical data for its lead product candidates. The company announced a significant cash position, expected to fund operations into mid-2025, and noted a reduction in operational losses compared to the previous year. A new Chief Financial Officer was appointed to help advance its clinical pipeline. The company plans to present further clinical data at the upcoming ASH annual meeting in December.
Read more →VORVor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Vor Bio has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi brings extensive experience from over twenty-five years in investment management and corporate strategy in the pharmaceutical sector. His role is expected to enhance Vor Bio's strategic goals, particularly in advancing its clinical pipeline for blood cancer treatments. However, the company has issued forward-looking statements cautioning about the uncertainties inherent in clinical trials and regulatory approvals.
Read more →VORNew Clinical Data Validates Vor Bio s Approach of Using Shielded Transplants to Deliver Targeted Therapies Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33
Vor Bio has announced promising new clinical data from its Phase 1/2 VBP101 study involving the combination of trem-cel and Mylotarg for patients with relapsed/refractory AML. The data indicates reliable engraftment and a broadened therapeutic window while shielding patients from toxicity. Dr. Eyal Attar highlighted the potential benefits for patients facing poor outcomes after transplant. Vor Bio plans to discuss a pivotal trial design with the FDA by the end of the year and continues to explore additional opportunities for their platform.
Read more →VORVor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
Vor Bio has reported its financial results for Q2 2024 and provided an update on its clinical trials. The company is making good progress in enrolling patients for its trem-cel + Mylotarg and VCAR33ALLO clinical trials, with important updates expected in the second half of 2024. Financially, Vor Bio's cash position remains strong, allowing them to fund operations through 2025, despite a net loss of $27.8 million this quarter. The potential of trem-cel in treating AML and MDS post-transplant represents a promising advancement in the field.
Read more →VORVor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
Vor Bio has released its financial results for Q1 2024, showing strong progress in its clinical trials for VCAR33ALLO and trem-cel. The trem-cel trial is now expanded to include patients with myelodysplastic syndromes, while the company anticipates key data updates in the second half of 2024. Despite the positive advancements, Vor Bio reported a net loss of $30.8 million, reflecting increased research expenses. The appointment of Dr. Fouad Namouni to the Board aims to enhance its oncology and cancer immunotherapy expertise.
Read more →VORVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
Vor Bio has appointed Dr. Fouad Namouni to its Board of Directors, bringing significant expertise in oncology and cancer immunotherapy. Currently the President of Research & Development at Blueprint Medicines, Dr. Namouni has over two decades of experience in clinical development. His leadership is expected to support Vor Bio's endeavors towards developing targeted therapies for acute myeloid leukemia. The company aims to advance its clinical pipeline through his strategic insights.
Read more →VORVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Vor Bio has reported its financial results for Q4 and the full year of 2023, highlighting foundational progress and positive developments for its lead product candidate VCAR33ALLO. The FDA has granted Fast Track and Orphan Drug Designations for VCAR33ALLO, which is undergoing clinical trials with initial data expected in late 2024. The company also confirmed that its cash reserves are sufficient to fund operations through the latter half of 2025. However, they reported an increased net loss compared to the previous year, indicating growing expenses associated with clinical trials.
Read more →VORVor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Vor Bio, a clinical-stage company specializing in cell and genome engineering, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is scheduled for a fireside chat on February 14, 2024, and will also host virtual one-on-one investor meetings. Vor Bio aims to improve treatment standards for blood cancer patients by engineering hematopoietic stem cells to facilitate targeted therapies after transplantation.
Read more →VORVor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Vor Bio has announced the dosing of its first patient in the VBP301 Phase 1/2 clinical trial for VCAR33ALLO, a new CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (AML). This significant milestone indicates the successful production of VCAR33ALLO in-house. The company has also extended its cash runway into the second half of 2025, ensuring continued investment in its clinical programs. Initial data from the VBP301 trial is anticipated later in 2024, with the therapy showing promise in addressing the needs of AML patients.
Read more →VOR▲ +10%on this news· ran to +39% by day 3
This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The word
Vor Biopharma Inc. has presented forward-looking information regarding its initiatives in curing blood cancers via cell and genome engineering. The presentation emphasizes the potential benefits of therapies like trem-cel and VCAR33ALLO in treating acute myeloid leukemia. It also highlights the company's capabilities in manufacturing and funding, with a cash runway projected through the second half of 2025. However, uncertainties remain about the outcomes of ongoing clinical trials and regulatory approvals.
Read more →VORVor Bio to Participate in the JMP Securities Hematology and Oncology Summit
Vor Bio has announced its participation in the upcoming JMP Securities Hematology and Oncology Summit, scheduled for December 5, 2023. The company will engage in a fireside chat and conduct virtual 1x1 investor meetings during the event. Vor Bio specializes in cell and genome engineering aimed at improving treatments for blood cancers. This participation underscores the company's commitment to advancing patient care in this critical area.
Read more →VORVor Bio Presents Positive Data Update on Trem-cel at HSCT Conference
Vor Bio presented positive clinical data on trem-cel at the HSCT conference, highlighting that all seven patients experienced successful neutrophil engraftment. Additionally, three patients showed satisfactory hematologic protection while receiving Mylotarg, which is a significant validation of Vor Bio's therapeutic approach. The results contributed to the understanding that trem-cel may provide both a durable response and a promising treatment option for patients with acute myeloid leukemia (AML). The next steps in the study involve dose escalation of Mylotarg to further assess its efficacy.
Read more →VOR▲ +9.3%on this newsshared move
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
Vor Bio has reported its financial results for the third quarter of 2023, highlighting a net loss increase to $33.2 million from $23.8 million in the same period last year. Positive developments include the upcoming data updates at the HSCT2 and ASH conferences, showcasing progress in their clinical programs, particularly with the VBP301 trial actively enrolling patients. The company is also expanding its scientific advisory board to enhance its research capabilities. Nonetheless, the rise in operational expenses signals financial challenges as they ramp up clinical activities.
Read more →VOR▲ +5.7%on this news· ran to +20% by day 3shared move
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio s Novel eHSC and CAR-T Platform - Three oral and two poster presentations accepted by ASH - Company to host call featuring Sarah K. Tasian, MD
Vor Bio (Nasdaq: VOR) announced that their novel eHSC and CAR-T platform will be prominently featured at the ASH 2023 Annual Meeting, highlighting significant advancements in treating acute myeloid leukemia (AML). The company's presentations include updates from key clinical trials, such as VBP101 and CD33CART, showcasing promising data on treatment efficacy and safety. Vor Bio aims to leverage their innovative approaches to improve outcomes for patients with blood cancers, particularly through the potential of enhanced engraftment and reduced toxicity.
Read more →VORVor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
Vor Bio reported its second quarter 2023 financial results, highlighting significant advancements such as the clearance of the FDA IND for VCAR33ALLO. The company is moving forward with its clinical trials for VBP101 and anticipates providing additional data by year-end 2023 regarding patient engraftment and treatment efficacy. Despite these developments, Vor Bio faces challenges including an increased net loss and escalating research and development expenses as it invests in its innovative therapies for blood cancers.
Read more →VORVor Bio to Participate in the Wedbush PacGrow Healthcare Conference
Vor Bio, a clinical-stage cell and genome engineering company, is set to participate in the 2023 Wedbush PacGrow Healthcare Conference. The event will feature in-person 1x1 investor meetings occurring on August 8-9, 2023, at the Lotte Palace Hotel in New York, NY. Vor Bio is focused on engineering hematopoietic stem cells with the goal of improving therapies for patients with blood cancers, highlighting their innovative approach to treatment.
Read more →VOR▼ -6.2%on this news
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio s Platform Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid dono
Vor Bio presented promising clinical data on its trem-cel therapy for acute myeloid leukemia (AML) at the EHA Congress. In a Phase 1/2a study, all five patients achieved primary neutrophil engraftment within 10-11 days. Although two patients faced complications, the overall engraftment and chimerism results are encouraging. The FDA has also cleared an IND application for another therapy, VCAR33ALLO, further indicating the potential of Vor Bio's platform.
Read more →VORVor Bio to Participate in the Goldman Sachs Healthcare Conference
Vor Bio, a clinical-stage cell and genome engineering company, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference. Scheduled for June 12, 2023, the event will include a fireside chat and in-person investor meetings. The company focuses on developing targeted therapies for blood cancers through innovative genome engineering techniques. Live coverage of the chat will be available on their investor website.
Read more →VORVor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
Vor Bio reported its financial results for the first quarter of 2023, showing a net loss of $28.4 million. The company is actively enrolling patients in its VBP101 clinical trial, with an update expected at the European Hematology Association 2023 Congress. Additionally, Vor Bio is on track for submitting the VCAR33ALLO IND in the first half of 2023. The cash position of $210.2 million is projected to fund operations into early 2025, despite increased R&D and G&A expenses.
Read more →VOR▼ -6.1%on this news
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Vor Bio has reported its fourth quarter and full year 2022 financial results, indicating a net loss of $23.9 million in Q4 and $92.1 million for the year. The company announced encouraging initial clinical results for VBP101 and aims to submit an IND for VCAR33ALLO in the first half of 2023. With a financing round extending its cash runway into Q1 2025, Vor Bio remains focused on the potential of its engineered hematopoietic stem cell therapies to improve treatment outcomes for patients with blood cancers.
Read more →VOR▼ -6.5%on this newsshared move
First AML Patient Transplanted with Vor Bio s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg TM Cycles at Initial Dose Level Trem-cel exhibited robust engraftment five months post-transplant through
Vor Bio presented clinical data indicating that its trem-cel therapy is showing promising results in patients with acute myeloid leukemia (AML). In a Phase 1/2a study, the first patient exhibited durable engraftment five months after receiving the transplant and tolerated the treatment well. A second patient has also shown successful engraftment, although the first patient later relapsed. The company plans to advance its studies and explore additional therapies using a CAR-T approach.
Read more →VORVor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
Vor Bio announced that clinical data from the first patient treated in its Phase 1/2a study of trem-cel has been accepted for a late-breaking poster presentation at the 2023 Tandem Meetings. This study focuses on patients with acute myeloid leukemia and aims to demonstrate the efficacy and safety of CD33-deleted hematopoietic stem cells. The presentation is scheduled for February 16-18 in Orlando, Florida, highlighting Vor Bio's commitment to innovating the treatment of blood cancers.
Read more →VORVor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
Vor Biopharma is set to participate virtually in the 3rd Annual Oncology Conference hosted by B. Riley Securities on January 18, 2023. The company, which specializes in cell and genome engineering for blood cancer therapies, aims to present its innovative approaches. A live webcast of the event will be available on their website, providing an opportunity for broader engagement. An archived version of the presentation will also be accessible after the event.
Read more →VOR▲ +41.9%on this news
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEWSWIRE) Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the prici
Read more →VOR▲ +41.9%on this news
First AML Patient Successfully Transplanted with Vor Bio s Investigational Trem-cel (VOR33) and Tolerated Mylotarg TM Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully m
First AML Patient Successfully Transplanted with Vor Bio s Investigational Trem-cel (VOR33) and Tolerated CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEWSWIRE) Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP
Read more →VORVor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for VOR33 on track for Q4 2022 Eyal C. Attar, M.D. appointed as Chief Medical Officer Initiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell
Read more →VORVor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinic
Read more →VORVor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Annual Congress CAMBRIDGE, Mass., Oct. 11,
Read more →VORVor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical manufacturing facility in Cambridge, Mass. co-located in the Company’s current headquarters.
Read more →VORVor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022 In-house manufacturing facility in Cambridge, MA operational in Q4 2022 Data presented at EHA successfully demonstrates in-vivo engraftment of multiplex edited HSCs for
Read more →VORVor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited hematopoietic stem and progenitor cells persisted long-term post engraftment, wit
Read more →VORVor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022 Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platform In-house manufacturing facility in Cambridge, MA operational in 2022 CAMBRIDGE, M
Read more →VORVor to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcoming investor conferences: BofA Securities
Read more →VORVor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held Apr
Read more →VOR▲ +8.7%on this news
Vor Bio Announces Retirement of Chief Medical Officer
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and conti
Read more →VOR▼ -9.5%on this news
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022 New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023 Cash runway extended into Q4 2023 providing additional financial flexibility and optionality CAM
Read more →VORVor to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in three upcoming investor conferences: Cowen’s 42nd Annual Hea
Read more →VOR▼ -7%on this news
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global He
Read more →VORVor to Participate in the JMP Securities Hematology and Oncology Summit
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities
Read more →VORVor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual
Read more →VORVor Reports Third Quarter 2021 Financial Results and Provides Company Update
VOR33 on track with initial clinical data expected in the first half of 2022 Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR),
Read more →VORVor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36th Annual M
Read more →VORVor to Present New Platform and Preclinical Data at ASH
Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted Therapies Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knock-out with High Engraftment Potential Dual-Mobilized Donor Der
Read more →VORVor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel engineered hematopoietic stem cell (eHSC) platform at the ESGCT Annual Congress, taking p
Read more →VORVor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor’s Senior Vice President of Program and Alliance Management. Dr. Schmelmer has mo
Read more →VORVOR33 Granted U.S. FDA Fast Track Designation for AML
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Company’s lead engineered hema
Read more →VORVor Reports Second Quarter 2021 Financial Results and Provides Company Update
On track to report initial VOR33 clinical data in the first half of 2022 Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignancies Initiated build-out of in-house clinical manufacturing facility CAMBRIDGE, Mass., Aug.
Read more →VORVor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a c
Read more →VORVor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manuf
Read more →VORVor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year period Kush M. Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures, to continue as a member of t
Read more →VORVor to Develop Multi-Targeted CAR-Ts with Abound Bio
CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments to be used
Read more →VORVor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang,
Read more →VORVor Reports First Quarter 2021 Financial Results and Provides Company Update
Health Canada clears the CTA for VOR33 clinical trial Vor to present on VOR33 manufacturing scale-up and in-depth genomic characterization at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Successful completion of Initial Public Offering raising $203.4 milli
Read more →VORVor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) is pleased to announce that Vor scientists will give two presentations documenting the development, manufacturing, and validation of its engineered hematopoietic stem cell (eHSC) clinical candidate V
Read more →VORVor Reports Fiscal Year 2020 Financial Results
IND accepted for VOR33, Vor’s lead eHSC product candidate for treatment of AML Completed initial public offering raising $203.4 million in total gross proceeds CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) (the Company), a cell therapy company
Read more →VORVor Biopharma to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participa
Read more →VORVor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participa
Read more →VORVor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares Mass., Feb. 9, 2021 Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted
Read more →VORVor Biopharma Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the pricing of its initial public o
Read more →Competitive Position
How VOR ranks across every disease it competes inCompetitive Position is a premium feature
See how VOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial